Structure Therapeutics Inc. (GPCR)
| Market Cap | 6.25B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -210.69M |
| Shares Out | 69.14M |
| EPS (ttm) | -3.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 942,059 |
| Open | 92.00 |
| Previous Close | 91.87 |
| Day's Range | 88.70 - 92.00 |
| 52-Week Range | 13.22 - 94.90 |
| Beta | -2.15 |
| Analysts | Strong Buy |
| Price Target | 103.09 (+14.08%) |
| Earnings Date | Feb 26, 2026 |
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an ora... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for GPCR stock is "Strong Buy." The 12-month stock price target is $103.09, which is an increase of 14.08% from the latest price.
News
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s
Structure Therapeutics CEO Ray Stevens talked about the biotech's path forward and his expectations for the future of the booming GLP-1 space.
Structure CEO Ray Stevens talks its obesity drug portfolio
Ray Stevens, Structure CEO, joins 'Fast Money' to talk its weigh-loss drug pipeline, potential M&A, and more.
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs
SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)
Structure Therapeutics (GPCR) delivered robust Phase 2b results for aleniglipron, surpassing key efficacy and tolerability thresholds for oral GLP-1 therapies. GPCR now appears competitive with top or...
Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript
Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript
Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at...
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump
Structure Therapeutics Inc. (NASDAQ:GPCR) shares shot up 100% to $68.95 after the company announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living wit...
Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?
Structure Therapeutics stock (NASDAQ: GPCR) rocketed above 103% Monday, trading near $70, after the clinical-stage biotech released promising mid-stage results for its oral obesity drug, aleniglipron....
Structure's experimental pill shows 11% weight loss in study, shares up
Structure Therapeutics said on Monday that its obesity pill showed a 11.3% reduction in weight in a mid-stage study.
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
Final Trade: UBER, CRWV, GPCR, DIS
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025
Fast Money: DAL, ROKU, AAPL, GPCR
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Structure Therapeutics Inc. (NASDAQ:GPCR) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Raymond Stevens - CEO & Director Conference Call...
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Viking Therapeutics, Inc. VKTX, Eli Lilly And Co LLY and Novo Nordisk A/S NVO stocks are trading higher on Monday.
Biotech stocks have been hit hard. Why they're a great value now.
Biotech is one of the U.S. stock market's most unloved sectors. But several indicators suggest that a bottom in sentiment could be near, and that's normally a good time to buy.
Structure Therapeutics CEO on latest GLP-1 developments
Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill.
Final Trade: PYPL, UBER, NKE, GPCR
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, al...